Paron Biotechnology

Paron Biotechnology is a China-based biopharmaceutical company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, specifically molecular glue degraders (MGDs). Founded in 2021 by industry veteran Dr. Jianwen Jiang, the company leverages a proprietary discovery platform to identify and optimize molecular glues for "undruggable" targets in oncology and immunology. Paron is backed by prominent venture capital firms including IDG Capital, Qiming Venture Partners, and 5Y Capital. The company's innovative approach aims to address significant unmet medical needs by expanding the scope of proteins that can be targeted by small-molecule modalities.